Allarity Therapeutics, Inc.

ALLR

NASDAQHealthcareBiotechnology

在 GoAI 中打開

GoAI 研究快照

簡明呈現最新可用的模型資訊。

2026年7月10日

36/ 100

GoAI評分

Sell

Trim exposure — unfavorable risk-reward

估值

Fair Value

動能

Weakening

情緒

Mixed

風險韌性

High Risk

完整 GoAI 研究

繼續查看更深入的依據、催化因素和風險。

看完整研究

人工智慧產生的上下文僅供參考，並非投資建議。

公司概況

公司網站

Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new cancer treatments. They utilize a unique "drug response predictor" technology to generate specific companion diagnostics, aiming to identify which patients will best respond to their various oncology therapeutics. The company's portfolio of investigational drugs for various cancers includes: Stenoparib: A poly-ADP-ribose polymerase (PARP) inhibitor currently in Phase 2 clinical trials for ovarian cancer. Dovitinib: A pan-tyrosine kinase inhibitor designed to treat renal cell carcinoma. IXEMPRA: A microtubule inhibitor used in the treatment of metastatic breast cancer. LiPlaCis: A liposomal formulation of cisplatin, undergoing Phase 2 clinical trials for metastatic breast cancer. 2X-111: A liposomal formulation of doxorubicin, also in Phase 2 studies for both metastatic breast cancer and glioblastoma multiforme. Established in 2004, Allarity Therapeutics maintains its headquarters in Cambridge, Massachusetts.

產業: Biotechnology
部門: Healthcare
總部: US
執行長: Thomas H. Jensen
上市以來: 2021年12月21日
僱員: 8